Korea’s stock disaster in 6/23/2026

 

Korea’s stock disaster in 6/23/2026

 

The peak performance of the Korean stock market was 95% before the crash. After the crash of 6/23/2026, the index, Samsung and SK Hynix were still profitable year-to-date but they had a big cut.  It crashed on 6/23/2026 and had not recovered since then as of this writing. There are lessons to be learned:

 

·        Diversification. Samsung and SK Hynix represent about 60% of the Korean market. We do not have this problem in the USA in our S&P 500 ETFs. If someone tells you he made millions in one or two stocks, he is just lucky and it is too risky for not diversified.

·        Never leverage. Do not use margin and leverage ETFs especially those ETFs with a few or even one stock.

·        Avoid stocks with low values. Check their P/E and Forward P/E. It may not be the case, but we should favor value better than momentum, especially on the money you cannot afford to lose.

·        Union. Samsung agreed to give 12% profit to the employees, and SK Hynix agreed with similar term.

·        Competition. A Chinese company is starting to produce memory and HBM, high bandwidth memory, that would eat into their profits, especially SK Hynix.

Interest Rates and the Economy

 

 Interest Rates and the Economy

 

Few economic forces are as powerful—or as politically charged—as the interest rate. Controlled by the Chairman of the Federal Reserve (an independent agency of the U.S. government), this single number influences everything from the price of gold to the health of the job market. Yet, while politicians often pressure the Chairman to lower rates in hopes of winning votes, the Fed's mandate is to prioritize the long-term health of the economy over short-term political gains. To better understand this complex relationship, I posed a few related questions to DeepSeek (AI). Here is the response:

---

"Yes, you have the textbook macroeconomic chain almost exactly right. However, the real world adds a few critical 'yes, but' caveats to each point. Here is the breakdown:

 

1. Gold Price (YES, generally)

Higher interest rates raise the opportunity cost of holding non-yielding gold and typically strengthen the U.S. dollar, which pressures gold downward.

 

The caveat: It's real interest rates (nominal rate minus inflation) that truly matter. If the Fed raises rates but inflation drops even faster, real rates rise sharply—which is crushing for gold. Conversely, if rates rise simply because inflation is spiraling out of control, gold can hold its ground.

 

2. Push Down Exports & Employment (YES, but with lags)

Higher rates attract foreign capital → the currency appreciates → exports become more expensive and less competitive abroad. This can reduce manufacturing output and hurt employment.

 

The caveats

:

• The "J-Curve" effect: In the very short term, a stronger currency might actually widen the trade deficit before it narrows.
• Employment lag: Jobs are a "lagging indicator." Businesses won't fire workers immediately unless rate hikes cause a severe recession. If domestic demand stays strong, employment might not fall at all, even if exports dip.

 

3. Attract Foreign Investment (YES, but it's a double-edged sword)

Higher bond yields make your country's debt securities look very attractive to global investors, leading to capital inflows.

 

The caveat: This works best if the rate hike is isolated (i.e., only your country is raising rates). If the rest of the world is raising rates too, the advantage shrinks. Also, if investors believe the rate hike will trigger a recession or a stock market crash, they might pull money out of your equities—meaning total foreign investment could actually fall despite higher bond yields.

 

4. Push Down Inflation (YES, this is the primary goal)

Higher borrowing costs cool down consumer spending (less credit card debt) and business investment (fewer loans for expansion), reducing aggregate demand and easing price pressures.

 

The caveat: Supply-side inflation (e.g., oil shocks, shipping disruptions, or food shortages) does not respond to rate hikes. If inflation is driven by supply constraints, higher rates will crush demand but fail to lower prices, leading to stagflation—which breaks your export/employment assumptions because you get high inflation and high unemployment simultaneously.

 

The Bottom Line

Your mental model is a perfect textbook summary of the transmission mechanism of monetary policy. In reality, the 'push down exports/employment' and 'push down inflation' parts often conflict. If the rate hike successfully crushes inflation, it usually weakens the economy enough that the currency doesn't actually rise that much, because markets start pricing in future rate cuts. The sequence is rarely linear—it's a messy tug-of-war between interest rates, market sentiment, and global trade flows."

 

A case study: August, 2026

 

·        Labor Market Shift: Employment figures have dipped following recent downward revisions, a common cyclical occurrence.

·        Consumer Impact: Rising job uncertainty typically curbs discretionary demand, particularly in rate-sensitive sectors like real estate and auto sales, depressing corporate revenue.

·        Monetary Policy Pressure: Weakening labor conditions push the Federal Reserve toward dovish policy shifts to support economic expansion.

·        Fiscal Drag: With national debt hovering near a record $40 trillion and interest service costs exceeding defense spending, rate cuts risk fueling inflation. However, we need to print more money to buy our own debts. It would depreciate our US dollar.

·        Asset Allocation: Lower real yields from rate cuts enhance the appeal of hard commodities, providing a tailwind for gold and silver. Most central banks are buying gold over our US dollar. It is just opposite to retail investors, who want to wait for lower prices before they buy.

 

14

The Shifting Landscape of US Pharmaceuticals

 

            The Shifting Landscape of US Pharmaceuticals

Recent developments (as of August, 2026—such as high-profile licensing of Chinese assets and breakthroughs like potential functional cures for type 1 diabetes—highlight a fundamental shift in the global pharmaceutical landscape.

 

China is rapidly evolving into an innovation hub for drug discovery. This transformation is driven by several structural advantages:

 

• Human Capital: A surge in high-quality STEM graduates, bolstered by foreign-trained scientists returning from Western institutions ("sea turtles").
• Policy Support & Efficiency: Favorable government backing alongside lower regulatory and clinical trial overhead.
• Large Patient Base: Extensive populations that accelerate clinical trial recruitment and serve as a massive domestic market.

 

For US drug giants, this shift means drug discovery will increasingly originate abroad. Strategic success will depend less on internal discovery alone and more on commercialization, capital allocation, and cross-border licensing.

 

Key Investment Drivers & Risk Factor Analysis by asking AI

 

Evaluating long-term pharmaceutical investments requires balancing macro tailwinds against operational risks. The breakdown below details how four major US drugmakers—Eli Lilly (LLY), Bristol Myers Squibb (BMY), Merck (MRK), and Pfizer (PFE)—stack up across these critical factors.

 

Investment Factor	Eli Lilly (LLY)	Bristol Myers Squibb (BMY)	Merck (MRK)	Pfizer (PFE)
Aging Population	★★★★★	★★★★★	★★★★★	★★★★★
Obesity & Diabetes Exposure	★★★★★	★★	★★	★★
Oncology Exposure	★★★	★★★★★	★★★★★	★★★
Chinese Biotech Competition	⚠️ High	⚠️ Medium	⚠️ Medium	⚠️ Medium
Licensing Innovation Capability	★★★★★	★★★★	★★★★★	★★★★★
Patent-Cliff Risk	★★	★★★★★	★★★★★	★★★★
Price & Policy Pressure	★★★★	★★★	★★★	★★★
Pipeline Replacement Need	★★★★★	★★★★	★★★★	★★★★
Valuation Risk	★★★★★	★★	★★★	★★

 

(Note: ★ indicates a favorable dynamic, except for rows explicitly marked as risks/pressures).

 

 

 

Financial & Quantitative Snapshot

Traditional valuation metrics like single-year Price-to-Earnings (P/E) can be misleading in pharma. A high Earnings Yield (EY) often reflects impending patent cliffs, while a lower yield may reflect priced-in growth.

 

Quantitative Metric	Eli Lilly (LLY)	Bristol Myers Squibb (BMY)	Merck (MRK)	Pfizer (PFE)
Earnings Yield (EY %)	~3%	~10%	~6%	~10%
Debt-to-Equity Ratio	1.6	2.0	1.3	0.7
Insider Transactions	0%	0%	-5%	+2%
Short Interest (%)	~1%	~3%	~1%	~3%

 

Key Takeaways:

1. Capital Structure: The sector relies moderately to heavily on leverage to fund acquisitions and capital expenditure, with Debt-to-Equity ratios ranging from 0.7 to 2.0.
2. Market Sentiment: Low overall short interest (~1% to 3%) suggests that the broader market is not aggressively betting against these major players.

 

Categorizing the 10-Year Outlook

Over a 10-year horizon, standard point-in-time valuation models fall short. Evaluating pharma stocks requires viewing them through two distinct strategic buckets:

 

1. Secular Growth Leader: Eli Lilly (LLY)

• The Opportunity: Unprecedented tailwinds from the expansion of metabolic and obesity therapies.
• The Risk: Extremely high market expectations reflected in a tight Earnings Yield (~3%). Valuation risk remains its primary vulnerability if growth decelerates.

 

2. Value, Pipeline & Patent Replacement: BMY, MRK, and PFE

• The Opportunity: High current Earnings Yields (~6–10%) and manageable valuation multiples offer value-oriented Entry points.
• The Risk: Heavy exposure to upcoming blockbuster patent expirations (e.g., Keytruda for Merck, Eliquis/Opdivo for BMY).

 

Core Takeaway for Investors

When assessing pharma stock performance over a decade, a patent cliff should not be evaluated in isolation.

 

The true metric of survival and outperformance is a firm's capacity to replace expiring revenue streams—whether through internal R&D, strategic acquisitions, or cross-border licensing of Chinese innovation. Pipeline depth and deal-making capability matter far more than current P/E or yield figures alone. Comparing Forward Earnings Yield (more useful sor a year or so than P/E) alongside dividend yields, pipeline quality, and overseas licensing exposure provides a far clearer picture of long-term risk-adjusted returns.

 

Use the above logic and feeding the right factors to AI for your own evaluation of the same or other sectors. AI would save you a lot of research time.  If you do not use AI, you need to compete with those who do.

 

Gemini (AI): “By showing how to feed targeted qualitative inputs (STEM demographics, sea-turtle returns, regulatory differences) alongside quantitative ratios into an AI workflow, you provide readers with a blueprint for modern investment research—directly reinforcing your point that investors must leverage these tools to remain competitive.”